We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 296

Totality of Evidence Must Be Considered in Assessing Obviousness
  • McDermott Will & Emery
  • USA
  • December 29 2017

The US Court of Appeals for the Federal Circuit reversed a finding of non-obviousness, concluding that the district court clearly erred in relying on


Antitrust Remains in Political Crosshairs for 2018 Midterm Elections
  • McDermott Will & Emery
  • USA
  • December 14 2017

Senator Elizabeth Warren (D-MA) gave a speech at the Open Markets Institute on December 6 entitled “Three Ways to Remake the American


McDermott's Reverse Engineered Podcast Five Hot FDA Issues for Life Science Companies
  • McDermott Will & Emery
  • USA
  • November 30 2017

Health-related technology is growing at an accelerating rate, as is its demand. The Food and Drug Administration (FDA), as the gatekeeper


FDA Publishes Supplemental Guidance on Menu Labeling for Chain Restaurants
  • McDermott Will & Emery
  • USA
  • November 20 2017

On November 7, the US Food and Drug Administration (FDA) published the latest in a series of industry draft guidance documents to help implement menu


Anticipated Acts of Infringement May Establish Venue for Hatch-Waxman
  • McDermott Will & Emery
  • USA
  • October 31 2017

Addressing venue in the context of Hatch-Waxman litigation, the US District Court for the District of Delaware held that venue is proper in Delaware


Another State Alleges False Claims Act Violation to Combat Opioid Crisis
  • McDermott Will & Emery
  • USA
  • October 26 2017

On October 5, 2017, the State of New Jersey sued Insys Therapeutics, Inc. (Insys), alleging that the company improperly marketed and promoted the


FDA Proposes to Extend Compliance Dates for Nutrition and Supplement Facts Labels and Serving Size
  • McDermott Will & Emery
  • USA
  • September 29 2017

On September 29, 2017, the US Food & Drug Administration (FDA) announced a proposal to extend the compliance dates for the Nutrition Facts and


FDA’s Delay of the Menu Labeling Rule Challenged
  • McDermott Will & Emery
  • USA
  • June 29 2017

Two consumer advocacy groups recently sued the Food and Drug Administration (FDA) for delaying the compliance deadline for the agency's 2014 menu


Biosimilar Notice May Be Given Prior to FDA Approval
  • McDermott Will & Emery
  • USA
  • June 26 2017

In a unanimous decision, the Supreme Court of the United States explained that under the Biologics Price Competition and Innovation Act of 2009


Supreme Court Analyzes Key Provisions of Biologics Price Competition and Innovation Act of 2009
  • McDermott Will & Emery
  • USA
  • June 20 2017

In a unanimous decision, the United States Supreme Court has clarified certain portions of the Biologics Price Competition and Innovation Act